Clinical trials: Ventricular Hypertrophy
Fabry Disease, Left Ventricular Hypertrophy
Viennese Prevalence Study of Anderson-Fabry Disease
The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.
- Trial name
- VIEPAF (NCT00871611)
- Where
- Austria
- Volunteers
- 4,000 people
- Sponsor
- Medical University of Vienna
End-Stage Renal Disease, Hemodialysis
Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis
The investigators hypothesize that an increase in the duration of dialysis session in thrice weekly center hemodialysis may provide better outcome, less morbidity, higher quality of life, lesser requirement of medications, and…
- Trial name
- NCT00413803
- Testing
- 4-hour thrice weekly in center hemodialysis, 8-hour thrice weekly in center hemodialysis
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 410 people
- Sponsor
- Ege University
Aortic Stenosis
Clinical Significance of Collagen Metabolism Changes in Left Cardiac Ventricle
As there are no clinical data in cardiology about the relationship between metabolism collagen changes and their clinical significance, the investigators will check the hypothesis that collagen metabolism changes, detected by…
- Trial name
- NCT00693797
- Where
- Czechia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Charles University, Czech Republic
Hypertrophic Cardiomyopathy
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
- Trial name
- PIONEER-OLE (NCT03496168)
- Testing
- mavacamten
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Myocardial Infarction
Diffusion MRI in Heart Failure
The development of symptomatic heart failure is frequently preceded by a pre-clinical period of structural remodeling in the heart. The remodeling process driving this transition, however, remains poorly understood.
- Conditions
- Heart Failure, Myocardial Infarction, Left Ventricular Hypertrophy
- Trial name
- NCT02973633
- Testing
- Diffusion Tensor MRI (DTI), Gadolinium DOTA Meglumine
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction).
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia
- Trial name
- PEACH (NCT07120776)
- Testing
- Camzyos (Mavacamten)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Manchester
Hypertension, Left Ventricular Hypertrophy
Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension
The study hypothesis is stress-related regional tissue dynamics is related to left ventricular outflow tract blood flow.
- Trial name
- NCT01442116
- Testing
- stress echocardiography
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Mustafa Kemal University
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Left Ventricular Hypertrophy
Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study
This is a prospective, open label, single-center study, in kidney transplant recipients with stable renal function for 12 and 120 months after transplantation, that are in use use of calcineurin inhibitors, azathioprine, and…
- Trial name
- NCT02493465
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto de Urologia e Nefrologia
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
The purpose of this study is to assess the effectiveness of squat-to-stand maneuver in eliciting left ventricular outflow gradients in patients with Hypertrophic Cardiomyopathy (HCM) compared to Valsalva, amyl nitrite inhalation…
- Conditions
- Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Cardiomyopathy, Hypertrophic
- Trial name
- NCT04905173
- Testing
- Squat-to-stand maneuver, Amyl nitrite inhalation, Valsalva
- Sponsor
- Mayo Clinic
Aortic Valve Stenosis, Ventricular Hypertrophy
Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis
The purpose of the study is to see if statin therapy will optimize myocardial response to cardiopulmonary bypass during aortic valve replacement (AVR) for aortic valve stenosis (AVS) (Phase I) and optimize left ventricular…
- Trial name
- NCT00811330
- Testing
- Atorvastatin 80 mg
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
Hypertension, Left Ventricular Hypertrophy
Hypertension in Hemodialysis
How high blood pressure in hemodialysis patients should be diagnosed and treated using medications or without medications is the purpose of this study.
- Trial name
- NCT00067665
- Testing
- Ultrafiltration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Left Ventricular Hypertrophy
Demographical and Clinical Profile of Patients With Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) is the most common result of the heart trying to pump blood against the high afterload, as in hypertension and aortic stenosis.Although hypertension is the most common cause of LVH, LVH can also…
- Trial name
- NCT04275882
- Testing
- Electrocardiogram
- Where
- Turkey (Türkiye)
- Volunteers
- 886 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Hypertension, Left Ventricular Hypertrophy
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.
- Trial name
- NCT01425411
- Testing
- valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Mustafa Kemal University
Type 2 Diabetes, Left Ventricular Hypertrophy
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
Left ventricular hypertrophy (LVH) is common in people with type 2 diabetes (70%) and is the strongest independent risk factor for cardiovascular events and all-cause mortality that there is.
- Trial name
- DAPA-LVH (NCT02956811)
- Testing
- Dapagliflozin
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- University of Dundee
Cardiomyopathy, Hypertrophic
Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Wall Thickness> 15mm
The investigators sought to evaluate the morphological and functional changes and prognosis of participants with unexplainable precordial deep T-wave inversion on ECG and with apical thickness less than 15mm.
- Trial name
- NCT02692508
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
This study will examine the effectiveness of the drug cyclosporine in treating hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens.
- Trial name
- NCT00001965
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Arterial Stiffness, CHRONIC RENAL FAILURE
Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.
The aims of the presented study are as follows: 1. To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry. 2.
- Conditions
- Arterial Stiffness, CHRONIC RENAL FAILURE, Left Ventricular Hypertrophy
- Trial name
- NCT01579032
- Where
- 2 sites in Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hypertension Complicated, Hypertrophy, Left Ventricular
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated…
- Conditions
- Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
- Trial name
- BVreduce (NCT03180593)
- Testing
- Valsartan 80 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Trinity Hypertension & Metabolic Research Institute